Health
3 days ago
Eli Lilly wins Mounjaro heart risk approval
Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk
Read more
2 months ago
Eli Lilly declares Q3 2026 dividend of $1.73 per share
Eli Lilly (NYSE:LLY) announced that its board of directors has declared a cash dividend of $1.73 per share on outstanding common stock for the third quarter of 2026
Read more
2 months ago
Eli Lilly completes acquisition of Centessa Pharmaceuticals
Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders
Read more
Health
19 days ago
Eli Lilly files six lawsuits over retatrutide sales
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement
Read more
